Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Change in Receivables (2016 - 2025)

Historic Change in Receivables for CorMedix (CRMD) over the last 10 years, with Q3 2025 value amounting to $87.3 million.

  • CorMedix's Change in Receivables rose 40794.3% to $87.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.9 million, marking a year-over-year increase of 55731.03%. This contributed to the annual value of $51.8 million for FY2024, which is N/A changed from last year.
  • CorMedix's Change in Receivables amounted to $87.3 million in Q3 2025, which was up 40794.3% from -$11.7 million recorded in Q2 2025.
  • Over the past 5 years, CorMedix's Change in Receivables peaked at $87.3 million during Q3 2025, and registered a low of -$11.7 million during Q2 2025.
  • For the 4-year period, CorMedix's Change in Receivables averaged around $10.0 million, with its median value being $1155.0 (2022).
  • The largest annual percentage gain for CorMedix's Change in Receivables in the last 5 years was 182572.89% (2021), contrasted with its biggest fall of 129069.57% (2021).
  • Quarter analysis of 4 years shows CorMedix's Change in Receivables stood at $47354.0 in 2021, then tumbled by 99.07% to $440.0 in 2022, then soared by 7818794.77% to $34.4 million in 2024, then soared by 153.67% to $87.3 million in 2025.
  • Its Change in Receivables stands at $87.3 million for Q3 2025, versus -$11.7 million for Q2 2025 and $3.0 million for Q1 2025.